Let Us File Your Lawsuit!

Drug companies have an obligation to inform the public about any harmful side effects of drugs they create and market. When a drugmaker fails to provide adequate warnings about the risks related to the use of a particular drug, it could be held liable in lawsuits for injuries and damages that may result. Let us help you get a qualified opinion on your potential Ranitidine lawsuit. We will charge no fee unless your case is successful.

Zantac’s Active Ingredient – Ranitidine – is Found to Increase the Risk of Cancer

On September 9, 2019, Valisure, LLC and ValisureRX, LLC submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) to request the Commissioner of Food and Drugs to issue a regulation, revise industry guidance, request a recall, and suspend sales of ranitidine from the US market.  The full petition may be read here.

Zantac is used to treat the following conditions:

Acid Indigestion

 Heart Burn

 Erosive Esophagitis

 Gastroesophageal Reflux Disease (GERD)

 Zollinger-Ellison Syndrome

 Zantac has been Found to Contain High Levels of the Cancer Causing Chemical, NDMA

The Zantac lawsuits claim that Zantac can be contaminated with the cancer-causing substance N-nitrosodimethylamine (NDMA). 

What is NDMA? 
NDMA is used in aviation and rocket fuel and industrial lubricants. It is also a by-product of several industrial processes, including gasoline refining and the treatment of wastewater containing nitrogen. Other applications for NDMA include inducing carcinogenesis in laboratory rats for cancer research.
The exact cause of the NDMA contamination in Zantac and other generic heartburn medications is still under investigation. However, during the period in which Boerhinger Ingelheim and Sanofi manufactured and marketed Zantac, scientific research demonstrated a clear link between ranitidine, the active ingredient in Zantac, and NDMA.

Despite the availability of this information, the drugmakers chose not to disclose this risk to the government or to consumers.  For years, due to a very high perception of ranitidine’s safety, Zantac and its generic equivalents were heavily prescribed to adults and infants and sold over-the-counter.

The FDA has issued a total recall and removal of Zantac from store shelves due to an unacceptably high cancer risk.

FDA RECALL

FDA Confirms Carcinogens

Our website privacy policy addresses the kinds of information we may gather about you when you visit or submit forms via our firm website. It explains how we expect to use that information, and the choices you have regarding our use of the information.

This website privacy policy applies only to the web pages of The Poole Law Group at www.poolelg.com and not to outside websites that you might visit by following links from our pages. We encourage you to review the privacy policy of any external website before disclosing any information to that site. We reserve the right to change our website privacy policy at any time and for any reason, as permitted or required by applicable law, by posting changes to this page or a subsequent privacy page. Nothing contained in this website privacy policy is intended to create a contract or agreement between The Poole Law Group and any firm, website visitor or information requester.

Our firm website automatically logs IP address information transmitted by your server, which may identify you or your Internet service provider’s Internet domain, but which normally would not include individually identifiable information such as your email address. You may browse our firm website without disclosing any additional information to us, although certain services and features may be unavailable unless you provide us additional information.

You may voluntarily choose to submit forms on our firm website or send us email to request information on our services or to provide us with feedback. You should NOT send us any confidential information describing your legal problems or requesting advice on legal matters. See our disclaimer below for more information.

We use visitor logs to monitor and improve the performance of our firm website, including navigation, links, search terms, and page and image load times. If you choose to provide us with identifying information through a form or email, we will use it to facilitate fulfillment of your requests. We may also store your identifying information, and may use that information for future communications from The Poole Law Group to you as necessary to respond to and process your requests. To update your contact information, unsubscribe to any of our mailing lists, or learn more about our mailing lists, please contact us.

The Poole Law Group does not disclose identifying information to third parties, except under the following limited circumstances:

1. In the case of mass tort or class action litigation, we work in conjunction with the firm of Levin, Papantonio of Pensacola, Florida. Your information may be shared with Levin, Papantonio for that purpose.

Your information may be incidentally accessible to third parties providing system administration, maintenance, or other services for our firm website, networks, servers, communications, or databases. However, we do not permit such third parties to use that information for other purposes.

1. We may provide your information to governmental agencies or other third parties as required by laws and regulations, including, for example, responding to subpoenas or other legal process.

We may keep contact information about information requesters as long as we deem it appropriate to fulfill the requests, maintain records of delivered information, or conduct marketing activities.

We use reasonable efforts to record and store data accurately when it is submitted to us through our firm website. We do not assume any responsibility for verifying the ongoing accuracy of identifying information after it has been submitted.

No system, especially a system connected to the Internet, can be guaranteed to be secure, but we follow generally accepted practices of physical, network, and operational security to safeguard our data, including information we may collect from visitors to our firm website.

Our website is targeted to businesses, governmental entities, and adult individuals who may be interested in our legal services. The firm website is not designed for or directed to children under 14 years of age, and we do not expect children to be attracted to or to use the firm’s website. We do not knowingly collect or maintain information from children, and will delete any such information if it is brought to our attention.

To learn more about our website privacy policy, please contact the firm.

Click to read our Privacy Policy here.

Disclosure & Disclaimer

The information on this site is intended as general information only and not as specific legal advice. The communication of information to, and the receipt of information from, this site and those connected with and maintaining this site does not and is not intended to establish an attorney-client relationship. Users should be aware that until they have spoken with one of our attorneys who has completed a conflict check and established an attorney-client relationship, resulting in a signed retainer agreement, any communication including email communication cannot be treated as privileged or confidential. Visitors to this site should not act on the information found at this site, but should seek professional legal counseling relating to his/her specific matter(s). Attorneys at the firm would be pleased to speak with interested parties. The firm is not interested in representing anyone who is selecting counsel based only on the information contained at this site if this information does not comply with the legal and ethical requirements of the reader’s state or country.

The Poole Law Group website contains references to various matters that have been handled by The Poole Law Group. The results portrayed in those matters were dependent upon the facts of those particular cases, and results will differ if based on different facts. This site also contains references to past and present clients. Such references are not intended to be testimonials or endorsements of The Poole Law Group and they do not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter. Each case is different. Past success does not guarantee a favorable result in any future case.

The Poole Law Group assumes no liability for the use or interpretation of information contained herein. This publication is provided “as is” without warrant or any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement.

On September 13, 2019, the U.S. Food and Drug Administration (FDA) reported the discovery of the carcinogenic contaminant N-nitrosodimethylamine (NDMA) in Zantac (ranitidine), a common heartburn medication available in both prescription and over-the-counter versions. See September 2019 FDA Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. 

In April of 2020, the FDA announced that all Zantac brand heartburn drugs, prescription and over-the-counter, should be immediately pulled from the market because of potential NDMA contamination.